{"title":"The current progress and futural prospects of ultrasound-targeted microbubble destruction for liver diseases: a narrative review.","authors":"Bing-Jie Yang, Hai-Feng Zhou, Yu Liu, Wei Yang, Jia Li, Wei-Zhong Zhou","doi":"10.21037/tgh-24-53","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Ultrasound (US)-targeted microbubble (MB) destruction (UTMD) involves the application of low-intensity US to MBs. This review is to illustrate the current progress and futural prospects of UTMD for liver diseases.</p><p><strong>Methods: </strong>A review of the most recent literature concerning the use of UTMD for liver diseases is presented from January 2000 to December 2023. A comprehensive search was conducted by two independent reviewers. In this review, we provide an overview of various preclinical applications of UTMD in the delivery of drugs and genes to target liver diseases, including liver cancer, liver fibrosis, and hepatic gene deficiency disorders, which have established the safety and effectiveness.</p><p><strong>Key content and findings: </strong>A total of 9 studies and 14 studies were identified about the preclinical applications for drug-loaded and gene-loaded UTMD for liver diseases, respectively. UTMD allows specific substances to bypass physiological barriers and reach target tissues or organs. It has been demonstrated to enhance hepatic disease drug delivery. UTMD still requires improvement in many areas, including sonographic parameters, drug-loading capacity, and range of treatable diseases.</p><p><strong>Conclusions: </strong>UTMD was shown in preclinical studies to enhance the therapeutic efficacy of drug delivery and gene therapy for liver cancer, liver fibrosis and hepatic gene defect diseases. Further clinical trials are emergent to evaluate the safety, effectiveness and long-term efficacy of UTMD in treating human liver diseases.</p>","PeriodicalId":94362,"journal":{"name":"Translational gastroenterology and hepatology","volume":"10 ","pages":"14"},"PeriodicalIF":3.8000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811551/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational gastroenterology and hepatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21037/tgh-24-53","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objective: Ultrasound (US)-targeted microbubble (MB) destruction (UTMD) involves the application of low-intensity US to MBs. This review is to illustrate the current progress and futural prospects of UTMD for liver diseases.
Methods: A review of the most recent literature concerning the use of UTMD for liver diseases is presented from January 2000 to December 2023. A comprehensive search was conducted by two independent reviewers. In this review, we provide an overview of various preclinical applications of UTMD in the delivery of drugs and genes to target liver diseases, including liver cancer, liver fibrosis, and hepatic gene deficiency disorders, which have established the safety and effectiveness.
Key content and findings: A total of 9 studies and 14 studies were identified about the preclinical applications for drug-loaded and gene-loaded UTMD for liver diseases, respectively. UTMD allows specific substances to bypass physiological barriers and reach target tissues or organs. It has been demonstrated to enhance hepatic disease drug delivery. UTMD still requires improvement in many areas, including sonographic parameters, drug-loading capacity, and range of treatable diseases.
Conclusions: UTMD was shown in preclinical studies to enhance the therapeutic efficacy of drug delivery and gene therapy for liver cancer, liver fibrosis and hepatic gene defect diseases. Further clinical trials are emergent to evaluate the safety, effectiveness and long-term efficacy of UTMD in treating human liver diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
